Vortioxetine for Treatment of Depressive Mood and Alcohol Use
Status:
Recruiting
Trial end date:
2021-04-04
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blinded, placebo-controlled, multicenter study. A total of 128
subjects will be randomly assigned to a test group or placebo group in a 1:1 ratio. Subjects
will receive vortioxetine (or placebo) and acamprosate for 6 weeks according to the treatment
group. Four visits will be made (weeks 0, 2, 4, 8), and on visit 2-4 (weeks 2, 4, 8)
compliance, depression symptoms, and alcohol craving will be assessed.